OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity vMYX-hIL-12/Dec produces functional ...
New research explores the spillover of myxoma virus from European rabbits to Iberian hares. In addition to shedding new light on species-jumping viruses, the study shows that the protein permitting ...
PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP ...
Odontogenic myxoma is an uncommon, benign neoplasm of odontogenic origin that presents a unique challenge owing to its locally aggressive behaviour and propensity for recurrence. The tumour arises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback